Prognostic Biomarkers in Endometrial Cancer : A Systematic Review and Meta-Analysis
Coll de la Rubia, Eva (Hospital Universitari Vall d'Hebron)
Martinez-Garcia, Elena (Quantitative Biology Unit, Luxembourg Institute of Health, L-1445 Strassen, Luxembourg; (E.M.-G.); (G.D.))
Dittmar, Gunnar (Quantitative Biology Unit, Luxembourg Institute of Health, L-1445 Strassen, Luxembourg; (E.M.-G.); (G.D.))
Gil-Moreno, Antonio 1965- (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Cabrera Díaz, Silvia (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Colás Ortega, Eva (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Universitat Autònoma de Barcelona

Fecha:	2020
Resumen:	Endometrial cancer (EC) is the sixth most common cancer in women worldwide and its mortality is directly associated with the presence of poor prognostic factors driving tumor recurrence. Stratification systems are based on few molecular, and mostly clinical and pathological parameters, but these systems remain inaccurate. Therefore, identifying prognostic EC biomarkers is crucial for improving risk assessment pre- and postoperatively and to guide treatment decisions. This systematic review gathers all protein biomarkers associated with clinical prognostic factors of EC, recurrence and survival. Relevant studies were identified by searching the PubMed database from 1991 to February 2020. A total number of 398 studies matched our criteria, which compiled 255 proteins associated with the prognosis of EC. MUC16, ESR1, PGR, TP53, WFDC2, MKI67, ERBB2, L1CAM, CDH1, PTEN and MMR proteins are the most validated biomarkers. On the basis of our meta-analysis ESR1, TP53 and WFDC2 showed potential usefulness for predicting overall survival in EC. Limitations of the published studies in terms of appropriate study design, lack of high-throughput measurements, and statistical deficiencies are highlighted, and new approaches and perspectives for the identification and validation of clinically valuable EC prognostic biomarkers are discussed.
Ayudas:	Ministerio de Economía y Competitividad CB16/12/00328 Ministerio de Economía y Competitividad RTC-2015-3821-1 Instituto de Salud Carlos III DTS17/00146 Instituto de Salud Carlos III PI17/02071 Instituto de Salud Carlos III PI17/02155 Instituto de Salud Carlos III IFI19/00029 Agència de Gestió d'Ajuts Universitaris i de Recerca 2017/SGR-16
Derechos:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Lengua:	Anglès
Documento:	Article ; recerca ; Versió publicada
Materia:	Endometrial cancer ; Protein biomarker ; Prognostic ; Prognosis ; Risk assessment ; ESMO-ESGO-ESTRO risk classification ; TCGA ; Endometrial adenocarcinoma ; Uterine cancer ; Recurrence
Publicado en:	Journal of clinical medicine, Vol. 9 (june 2020) , ISSN 2077-0383

DOI: 10.3390/jcm9061900
PMID: 32560580

20 p, 2.0 MB

El registro aparece en las colecciones:
Artículos > Artículos de investigación
Artículos > Artículos publicados